GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    American Association for Cancer Research (AACR) ; 2012
    In:  Cancer Research Vol. 72, No. 8_Supplement ( 2012-04-15), p. 1478-1478
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 72, No. 8_Supplement ( 2012-04-15), p. 1478-1478
    Abstract: Bone marrow mesenchymal stem cells (BMMSC) are recruited to primary tumors and have been reported to display pro-tumorigenic as well as anti-tumorigenic activities. However, the mechanisms behind their effect on tumor development are still unclear. We have isolated murine bone marrow aspirates and plated them on fibronectin/collagen I, which allows expansion of an adherent stromal cell population in 3-6 weeks. These cells express the CD44 hyaluronic acid receptor in the absence of hematopoietic (CD34), myeloid (CD45), and endothelial (CD31/VEGFR2) markers and display both spontaneous and inducible adipogenesis/ osteoblastogenesis in culture. 3D matrigel cultures of murine 4T1 mammary carcinoma cells revealed enhanced generation of tumor spheroids in the presence of BMMSC or their conditioned media. Conditioned media from BMMSC also increased 4T1 cell expansion in 2D monolayer cultures, with loss of this phenomenon after heat inactivation suggesting the presence of protein-based signaling. Cell cycle analysis of 4T1 cells treated with BMMSC conditioned media revealed no statistically significant change in mitotic potential in either growth (serum present) or growth-arrest (serum depleted) phase, as determined by PI staining and BrdU uptake. However, analysis of apoptosis in 4T1 cells treated with BMMSC conditioned media showed increased percentages of live cells by PI uptake and AnnexinV staining, as well as a reduction in caspase-3 and caspase-9 activation by colorimetric assay, as the cells entered growth arrest phase. Furthermore, treatment with BMMSC conditioned media preserved viability in 4T1 cells exposed to paclitaxel under no-serum conditions. Complementary studies of BMMSC tumor-directed migration indicate that BMMSC show preferential in vitro recruitment by murine tumor cell lines which generate reactive stroma (4T1, LL/2 lung carcinoma) vs. no stroma (B16 melanoma). In vivo recruitment of BMMSC by early-stage/slow-growing subcutaneous 4T1 tumors was also visualized by bioluminescent imaging, red fluorescence, and magnetic resonance imaging of BMMSC labeled with iron-nanoparticles. These results were confirmed by immunohistochemical evaluation of iron deposits by Prussian blue stain and by immunofluorescent detection of PKH26-labeled BMMSC. Overall, our data identify BMMSC as an important mediator of tumor cell survival/treatment resistance and reveal an enhanced tropism of BMMSC toward early 4T1 tumors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1478. doi:1538-7445.AM2012-1478
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2012
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 67, No. 19 ( 2007-10-01), p. 9346-9355
    Abstract: Metastasis to the bone is seen in 56% of patients with neuroblastoma and contributes to morbidity and mortality. Using a murine model of bone invasion, we have reported previously that neuroblastoma cells invade the bone by activating osteoclasts. Here, we investigated the antitumoral and antiosteolytic activities of zoledronic acid, a bisphosphonate inhibitor of osteoclasts, in combination with cytotoxic chemotherapy in our model. We first show that zoledronic acid given at the same time (early prevention) or 2 weeks after tumor cell injection (late prevention) significantly prevented the formation of severe osteolytic lesions. It also prevented formation of these lesions when given 4 weeks after tumor cell injection (intervention) when combined with chemotherapy including cyclophosphamide and topotecan. The combination of zoledronic acid + cyclophosphamide/topotecan also significantly improved survival (P & lt; 0.001). In mice treated with zoledronic acid, we observed a marked inhibition of osteoclasts inside the bone associated with a decrease in tumor cell proliferation and increase in tumor cell apoptosis. In vitro, zoledronic acid inhibited neuroblastoma cell proliferation and induced apoptosis, and these effects were significantly enhanced by the addition of 4-hydroxyperoxycyclophosphamide (4-HC). The proapoptotic effect of zoledronic acid and zoledronic acid in combination with 4-HC on tumor cells was associated with an increase in caspase-3 activity and a decrease in phosphorylated Bcl-2, Bcl-2, and Bcl-XL expression. Zoledronic acid inhibited the association of Ras with the plasma membrane and activation of c-Raf, Akt, and extracellular signal-regulated kinase 1/2. The data indicate that zoledronic acid, in addition to inhibiting osteoclasts, is active against tumor cells and suggest that zoledronic acid in combination with cytotoxic chemotherapy may be effective in children with neuroblastoma that has metastasized to the bone. [Cancer Res 2007;67(19):9346–55]
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    RVK:
    RVK:
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2007
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Ovid Technologies (Wolters Kluwer Health) ; 2006
    In:  Journal of Computer Assisted Tomography Vol. 30, No. 3 ( 2006-05), p. 525-534
    In: Journal of Computer Assisted Tomography, Ovid Technologies (Wolters Kluwer Health), Vol. 30, No. 3 ( 2006-05), p. 525-534
    Type of Medium: Online Resource
    ISSN: 0363-8715
    RVK:
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2006
    detail.hit.zdb_id: 2039772-0
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...